At the recent American Society of Hematology annual meeting, early data from the Mithic-FL1 Trial demonstrated impressive response rates with frontline mosunetuzumab (Lunsumio) in high-tumor-bulk ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The idea of requiring site-neutral payments in Medicare ...